Skip to main
ACAD

ACADIA Pharma (ACAD) Stock Forecast & Price Target

ACADIA Pharma (ACAD) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 42%
Hold 21%
Sell 0%
Strong Sell 5%

Bulls say

ACADIA Pharmaceuticals Inc. is strategically positioned for continued growth, with expectations of approximately $1.7 billion in combined net sales by 2028, fueled by strong performance and broader community uptake of its products NUPLAZID and DAYBUE. The company has demonstrated robust sales growth, particularly with DAYBUE, achieving $110 million in the most recent quarter, which exceeded consensus estimates and reflected a significant increase in the number of patients on therapy. Additionally, ACAD's proactive expansion of its field force, now fully deployed, is projected to enhance sales further, despite recent challenges due to inflation cap rebates affecting NUPLAZID sales.

Bears say

ACADIA Pharmaceuticals faces significant risks that contribute to a negative outlook, including challenges in gaining approval for additional indications, which could adversely impact growth and market performance. Recent negative feedback regarding the trofinetide launch in the EU, along with uncertainty around the intellectual property for both NUPLAZID and DAYBUE, raises further concerns about potential market uptake and pricing stability. Additionally, high dropout rates in clinical studies for trofinetide and mixed reviews from key opinion leaders on its efficacy diminish confidence in its therapeutic value, complicating the company's prospects in addressing unmet needs in rare diseases.

ACADIA Pharma (ACAD) has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 42% recommend Buy, 21% suggest Holding, 0% advise Selling, and 5% predict a Strong Sell.

This aggregate rating is based on analysts' research of ACADIA Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ACADIA Pharma (ACAD) Forecast

Analysts have given ACADIA Pharma (ACAD) a Buy based on their latest research and market trends.

According to 19 analysts, ACADIA Pharma (ACAD) has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ACADIA Pharma (ACAD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.